Corcept Therapeutics Incorporated. (CORT)

Corcept Therapeutics' stock price experienced a significant drop on December 31, 2025, following the FDA's Complete Response Letter for relacorilant, leading to securities class action lawsuits. In March 2026, the company received FDA approval for Lifyorli (relacorilant) for platinum-resistant ovarian cancer, supported by positive data from the Phase 3 ROSELLA trial in April 2026. Despite this approval, the stock traded lower in April 2026 due to ongoing litigation and insider sales. Between April 7, 2025, and April 2, 2026, the share price experienced a decline of 43.08%.

There is no explicit information indicating specific seasonal patterns in the demand for Corcept Therapeutics' products or services. The company has reported increasing demand for Korlym, driven by growing recognition among physicians of hypercortisolism's prevalence. The company noted that its financial results in Q3 2025 did not fully reflect the surge in demand due to capacity constraints with a previous specialty pharmacy vendor, and it has since added new vendors to meet this increasing demand.

Corcept Therapeutics is a pharmaceutical company focused on developing medications for severe metabolic, psychiatric, and oncologic disorders by modulating cortisol effects. Their flagship product is Korlym (mifepristone), approved for controlling hyperglycemia in adult patients with endogenous Cushing's syndrome who also have type 2 diabetes or glucose intolerance and are not candidates for surgery or have failed surgery. The company's pipeline includes relacorilant, under investigation for endogenous Cushing's syndrome and platinum-resistant ovarian cancer; Lifyorli (relacorilant), recently FDA approved for platinum-resistant ovarian cancer; miricorilant, in Phase 1b trials for MASH; and dazucorilant, being developed for ALS. Corcept also has a portfolio of over 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists.

Corcept Therapeutics is headquartered in Redwood City, California, United States. The company is a U.S.-based entity with primarily domestic sales, particularly for its marketed product Korlym, which is approved in the United States.

Corcept Therapeutics' brand reputation has been negatively impacted by the FDA's Complete Response Letter for relacorilant and subsequent securities fraud class action lawsuits. However, the recent FDA approval of Lifyorli (relacorilant) for platinum-resistant ovarian cancer and positive data from the ROSELLA trial could positively influence the company's reputation, though ongoing legal issues remain a near-term pressure.

Corcept Therapeutics Incorporated is largely controlled by institutional shareholders, who collectively own approximately 70% of the company. As of April 7, 2026, 401 institutional owners and shareholders held a total of 76,390,335 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, Ingalls & Snyder Llc, Renaissance Technologies Llc, Parallel Advisors, LLC, State Street Corp, Geode Capital Management, Llc, Fmr Llc, UBS Group AG, and Dimensional Fund Advisors Lp. Patrick G. Enright is identified as the largest individual shareholder, owning 44.80 million shares, representing 42.12% of the company.